Your AI-Trained Oncology Knowledge Connection!
Second-line treatment with pembrolizumab (Keytruda) did not significantly improve overall survival or progression-free survival in patients with advanced or metastatic gastric or gastroesophageal junction cancer with a PD-L1 combined positive score ≥1.
Michael Simon, MD, MPH, discusses advances in genetic testing for breast cancer, highlighting the overlap between genomic risk assessment and tumor genomic profiling.
TAS-120 demonstrated a clinically meaningful benefit with a manageable toxicity profile in patients with cholangiocarcinoma harboring FGFR2 gene fusions, including patients who had progressed on an FGFR inhibitor.
The combination of duvelisib and fludarabine-cyclophosphamide-rituximab demonstrated efficacy as a frontline treatment for younger patients with chronic lymphocytic leukemia.
The addition of polatuzumab vedotin to bendamustine and rituximab induced a higher rate of complete responses by PET scan compared with BR alone in patients with relapsed/refractory diffuse large B-cell lymphoma.
PET can be safely used to guide treatment in patients with untreated advanced-stage classical Hodgkin lymphoma after 2 cycles of upfront de-escalated BEACOPP.
Justin N. Baker, MD, discusses the benefits of a holistic approach to end-of-life care in pediatric oncology, as well as the importance of teaching palliative care to the next generation of oncologists and hematologists.
The CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (JCAR017; liso-cel) is showing promising response rates in patients with high-risk diffuse large B-cell lymphoma.
Long-term findings from a phase I study of trastuzumab deruxtecan showed that the investigational HER2-targeting antibody-drug conjugate had antitumor activity in multiple tumor types that expressed HER2 at varying levels.
Haythem Y. Ali, MD, discusses the state of biosimilar development and implementation in the field of oncology.
Gregory L. Beatty, MD, PhD, shares his insight on the challenges with sequencing immunotherapies in light of recent advancements in gastrointestinal malignancies.
Theodore H. Welling, MD, discusses the expanding role of surgery in hepatobiliary neoplasms.
Anne Chiang, MD, PhD, discusses recent developments with immunotherapy and the overall outlook for the treatment landscape of small cell lung cancer.
The CD19-targeted CAR T-cell product axicabtagene ciloleucel (axi-cel; Yescarta) is currently being investigated in patients with relapsed/refractory MCL in the ongoing ZUMA-2 trial.
Ivosidenib induced an overall response rate of 41.6% (95% CI, 32.9-50.8) in patients with IDH1-positive relapsed/refractory acute myeloid leukemia.
Carfilzomib (Kyprolis) administered once weekly at 70 mg/m2 with dexamethasone resulted in a prolonged PFS compared with the standard twice-weekly schedule in patients with relapsed/refractory multiple myeloma.
David M. Nanus, MD, discusses the promise of immunotherapy and the continued role of surgery in the treatment in renal cell carcinoma.
Susan N. Chi, MD, discusses the rationale for using tazemetostat in pediatric patients with INI1-negative rhabdoid tumors, as well as the future steps being taken with this treatment.
Birte Wistinghausen, MD, shares her insight on the potential for targeted therapies in the treatment of pediatric non-Hodgkin lymphoma, and the steps that the Children’s Oncology Group is taking to cure all patients with this disease.
Haythem Y. Ali, MD, discusses adjuvant advances in HER2-postitive breast cancer and emerging agents in the field.
Suresh S. Ramalingam, MD, sheds light on the recent data with emerging agents in small cell lung cancer.
Elisavet Paplomata, MD, discusses ABP 980 and the impact that biosimilars may have on global access to cancer care.
Anna Farago, MD, PhD, discusses the biology of larotrectinib, as well as the importance of genetic testing for molecular alterations like TRK in patients with locally advanced solid tumors.
Dennis J. Slamon, MD, PhD, and Sara A. Hurvitz, MD, discuss the impact of CDK4/6 inhibitors in ER-positive breast cancer.
Paul E. Oberstein, MD, discusses incorporating novel agents and sequencing approaches in advanced pancreatic neoplasms.
Anas Younes, MD, discusses the current and future state of CAR T-cell therapies and immune checkpoint inhibitors in the landscape of hematologic malignancies.
Selina Chen-Kiang, PhD, details the research being conducted with CDK4/6 inhibitors in mantle cell lymphoma.
Jeffrey Wolf, MD, emphasizes the importance of identifying risk when diagnosing patients with multiple myeloma.
Next-generation sequencing in metastatic non-small cell lung cancer can save Center for Medicare and Medicaid Services payers $1.4 million to $2.1 million.
Mike Janicek, MD, discusses the importance of genetic testing and how the ovarian field can benefit from a better understanding of it through genetic counselors and self-education.
